A Single-Center, Open-Label, Single Dose Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Emicizumab in Healthy Chinese Volunteers
Phase of Trial: Phase I
Latest Information Update: 01 Oct 2019
Price : $35 *
At a glance
- Drugs Emicizumab (Primary)
- Indications Haemophilia A
- Focus Pharmacokinetics
- Sponsors Roche
- 28 Sep 2018 Status changed from active, no longer recruiting to completed.
- 30 May 2018 Planned End Date changed from 30 Oct 2018 to 15 Sep 2018.
- 30 May 2018 Planned primary completion date changed from 1 Sep 2018 to 15 Sep 2018.